Assembly Biosciences Near Breakout; Key Clinical Trials in Focus
AI Prediction of Assembly Biosciences, Inc. (ASMB)
Assembly Biosciences, a clinical-stage biotech company focusing on hepatitis B cures, has shown promising developments in its drug pipeline and strategic collaborations. Given the upcoming clinical trial results and potential regulatory milestones, investors may find significant opportunities for growth.
ASMB Report Information
Prediction Date2025-07-03
Close @ Prediction$18.14
Mkt Cap484m
IPO DateN/a
AI-derived Information
Recent News for ASMB
- May 28, 4:05 pm — Assembly Biosciences Announces Upcoming Investor Conference Presentations (GlobeNewswire RSS)
- May 27, 9:00 am — FormAssembly Achieves DoD IL4 Status in Partnership With FedHIVE (GlobeNewswire RSS)
- May 26, 4:05 pm — Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares (GlobeNewswire RSS)
- May 22, 7:05 am — Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire RSS)
- May 22, 7:00 am — Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases (GlobeNewswire RSS)
- May 13, 2:00 am — Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026 (GlobeNewswire)
- May 11, 8:00 am — Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference (GlobeNewswire)
- May 7, 4:08 pm — Assembly Biosciences: Q1 Earnings Snapshot (Associated Press)
- May 7, 4:00 pm — Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights (GlobeNewswire)
- Apr 9, 8:00 am — Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026 (GlobeNewswire)
- Mar 19, 4:26 pm — Assembly Biosciences: Q4 Earnings Snapshot (Associated Press Finance)
- Mar 19, 4:05 pm — Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights (GlobeNewswire)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.